Literature DB >> 12493158

Single photon emission computed tomography perfusion imaging for assessment of myocardial viability and management of heart failure.

Steven Burrell1, Sharmila Dorbala, Marcelo F Di Carli.   

Abstract

In the setting of coronary artery disease, some areas of dysfunctional myocardium may realize significant improvement in function as a consequence of revascularization. These areas represent viable myocardium, encompassing a spectrum of pathophysiology ranging from chronic stunning, in which resting blood flow is preserved, to hibernating myocardium, in which resting blood flow is decreased. The accurate preoperative evaluation of viable myocardium helps identify those patients with left ventricular dysfunction who will most benefit from coronary revascularization. Of the various modalities available for viability assessment, the nuclear medicine techniques (201)Thallium and (18)Fluorodeoxyglucose positron emission tomography have emerged as the most sensitive. It has been consistently shown that in patients with a significant amount of viable myocardium, there is a substantial survival benefit in revascularization versus medical therapy. The likelihood of affecting a significant improvement decreases with time to revascularization, however, particularly in the setting of an enlarged left ventricle secondary to ventricular remodeling.

Entities:  

Mesh:

Year:  2003        PMID: 12493158     DOI: 10.1007/s11886-003-0035-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  46 in total

Review 1.  Myocardial 'stunning' in man.

Authors:  R Bolli
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

2.  The hibernating myocardium.

Authors:  S H Rahimtoola
Journal:  Am Heart J       Date:  1989-01       Impact factor: 4.749

3.  Left ventricular volume predicts postoperative course in patients with ischemic cardiomyopathy.

Authors:  A Yamaguchi; T Ino; H Adachi; S Murata; H Kamio; M Okada; J Tsuboi
Journal:  Ann Thorac Surg       Date:  1998-02       Impact factor: 4.330

4.  Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability.

Authors:  R W Burt; O W Perkins; B E Oppenheim; D S Schauwecker; L Stein; H N Wellman; R M Witt
Journal:  J Nucl Med       Date:  1995-02       Impact factor: 10.057

5.  Validity of 18F-fluorodeoxyglucose imaging with a dual-head coincidence gamma camera for detection of myocardial viability.

Authors:  S Hasegawa; T Uehara; H Yamaguchi; K Fujino; H Kusuoka; M Hori; T Nishimura
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

6.  Enhanced detection of viable myocardium by technetium-99m-MIBI imaging after nitrate administration in chronic coronary artery disease.

Authors:  S Maurea; A Cuocolo; A Soricelli; L Castelli; A Nappi; F Squame; M Imbriaco; B Trimarco; M Salvatore
Journal:  J Nucl Med       Date:  1995-11       Impact factor: 10.057

Review 7.  Predicting improved function after myocardial revascularization.

Authors:  M F Di Carli
Journal:  Curr Opin Cardiol       Date:  1998-11       Impact factor: 2.161

8.  Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging.

Authors:  R S Beanlands; P J Hendry; R G Masters; R A deKemp; K Woodend; T D Ruddy
Journal:  Circulation       Date:  1998-11-10       Impact factor: 29.690

9.  Assessment of myocardial perfusion and viability with technetium-99m methoxyisobutylisonitrile and thallium-201 rest redistribution in chronic coronary artery disease.

Authors:  C Rossetti; C Landoni; G Lucignani; G Huang; A L Bartorelli; M D Guazzi; A Margonato; S Chierchia; L Galli; A Savi
Journal:  Eur J Nucl Med       Date:  1995-11

10.  Dobutamine echocardiography predicts improvement of hypoperfused dysfunctional myocardium after revascularization in patients with coronary artery disease.

Authors:  P Perrone-Filardi; L Pace; M Prastaro; F Piscione; S Betocchi; F Squame; P Vezzuto; A Soricelli; C Indolfi; M Salvatore
Journal:  Circulation       Date:  1995-05-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.